Auto-HSCT linked to higher AML, MDS risk

Apheresis machine
Photo by Luis Alvaz
Patients undergoing autologous hematopoietic stem cell transplant (auto-HSCT) for lymphoma or myeloma have an increased risk of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), according to a retrospective study. The study suggested these patients have 10 to 100 times the risk of AML or MDS as the general population. The elevated risk also exceeds that of similar lymphoma and myeloma patients largely untreated with auto-HSCT. [Read Article]

Familial risk of myeloid malignancies

Three generations of
women in a family
A large study has revealed “the strongest evidence yet” supporting genetic susceptibility to myeloid malignancies, according to a researcher. The study showed that first-degree relatives of patients with myeloid malignancies had double the risk of developing a myeloid malignancy themselves, when compared to the general population. The researchers observed significant risks for developing acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), essential thrombocythemia (ET), and polycythemia vera (PV). [Read Article]

Group releases new CLL guidelines

Vials of drugs
Photo by Bill Branson
Fludarabine, cyclophosphamide, and rituximab are recommended as initial therapy for fit patients with chronic lymphocytic leukemia (CLL) who do not have TP53 disruption, according to new guidelines from the British Society for Haematology. The guidelines update the 2012 recommendations on CLL to include “significant” developments in treatment. The new guidelines were published in the British Journal of Haematology. [Read Article]